Limits...
Antibiotic resistance patterns in invasive group B streptococcal isolates.

Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB, Schrag SJ, Lynfield R - Infect Dis Obstet Gynecol (2009)

Bottom Line: Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001).Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001).While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

View Article: PubMed Central - PubMed

Affiliation: Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, MN 55164, USA.

ABSTRACT
Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996-2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001). Clindamycin resistance increased from 10.5% to 15.0% (X(2) for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

Show MeSH

Related in: MedlinePlus

Resistance invasive Group B streptococci isolates among pregnant women and newborns (perinatal) and non-pregnant adults (n =  2 887 isolates).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2637368&req=5

fig3: Resistance invasive Group B streptococci isolates among pregnant women and newborns (perinatal) and non-pregnant adults (n = 2 887 isolates).

Mentions: The proportion ofisolates resistant to clindamycin and erythromycin did not differ significantlybetween the perinatal and non-pregnant adult patient groups (see Figure 3). Within the perinatal group, the overall clindamycin resistance was 13.1%, withno significant changes between the early-onset (14.9%), late-onset (10.3%), andmaternal populations (13.7%). Likewise, no significant differences inerythromycin resistance levels were identified between the different perinatalgroups (21.9% overall; 21.2% for early-onset, 22.1% for late-onset, and 23.9%maternal).


Antibiotic resistance patterns in invasive group B streptococcal isolates.

Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB, Schrag SJ, Lynfield R - Infect Dis Obstet Gynecol (2009)

Resistance invasive Group B streptococci isolates among pregnant women and newborns (perinatal) and non-pregnant adults (n =  2 887 isolates).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2637368&req=5

fig3: Resistance invasive Group B streptococci isolates among pregnant women and newborns (perinatal) and non-pregnant adults (n = 2 887 isolates).
Mentions: The proportion ofisolates resistant to clindamycin and erythromycin did not differ significantlybetween the perinatal and non-pregnant adult patient groups (see Figure 3). Within the perinatal group, the overall clindamycin resistance was 13.1%, withno significant changes between the early-onset (14.9%), late-onset (10.3%), andmaternal populations (13.7%). Likewise, no significant differences inerythromycin resistance levels were identified between the different perinatalgroups (21.9% overall; 21.2% for early-onset, 22.1% for late-onset, and 23.9%maternal).

Bottom Line: Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001).Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001).While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

View Article: PubMed Central - PubMed

Affiliation: Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, MN 55164, USA.

ABSTRACT
Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996-2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001). Clindamycin resistance increased from 10.5% to 15.0% (X(2) for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

Show MeSH
Related in: MedlinePlus